AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance
Portfolio Pulse from Vandana Singh
AbbVie announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab (Skyrizi) achieved the primary endpoint of clinical remission at week 52 in moderately to severely active ulcerative colitis patients. A significantly higher proportion of patients achieved clinical remission, endoscopic improvement, and steroid-free clinical remission with risankizumab compared to the induction-only control group.
June 15, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's risankizumab (Skyrizi) achieved the primary endpoint in a Phase 3 study for ulcerative colitis, showing significant improvement compared to the control group. This may positively impact the company's stock price.
The positive results from the Phase 3 study indicate that risankizumab (Skyrizi) is effective in treating ulcerative colitis, which may lead to increased demand for the drug and higher revenues for AbbVie. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100